Last reviewed · How we verify
Extended-Release Niacin
At a glance
| Generic name | Extended-Release Niacin |
|---|---|
| Also known as | Niaspan®, Niaspan, niaspan |
| Sponsor | Henry Ford Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nicotinic Acid for the Treatment of Alzheimer's Disease (PHASE1, PHASE2)
- Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine (PHASE2)
- Pathways of Eicosanoid Metabolism (EARLY_PHASE1)
- Effects of Niacin Therapy on Lipoprotein Composition and Function (NA)
- PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (PHASE1)
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (PHASE3)
- To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED) (PHASE3)
- Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended-Release Niacin CI brief — competitive landscape report
- Extended-Release Niacin updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI